Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Eli Lilly is set to launch Mounjaro in KwikPen, a user-friendly, prefilled pen for weekly administration, in India, following ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The ...

Mounjaro is one of the bestselling weight loss drugs. See what your options are if you want to invest in Mounjaro stock.